Amolyt Pharma
Created in 2014
Up & running (A)
Existing signals show a regular activitySocial networks
179 9,285 9,285Global tags
Activities
Technologies
Entity types
Location
15 Chem. du Saquin, 69130 Écully, France
Écully
France
Employees
Scale: 11-50
Estimated: 39
SIREN
803919729Engaged catalyst
12
0 0Added in Motherbase
4 years, 1 month ago
Value proposition
Advancing peptides for the treatment of rare endocrine and related diseases
Amolyt Pharma is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases.
Amolyt Pharma’s portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly.
Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors.
Hypoparathyroidism, Endocrinology, Metabolic Disease, Therapeutic Peptides, Endocrine Disease , and Rare DiseaseOriginal language
Advancing peptides for the treatment of rare endocrine and related diseases
Amolyt Pharma is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases.
Amolyt Pharma’s portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly.
Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors.
AstraZeneca - Research-Based BioPharmaceutical Company
AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
https://amolytpharma.com
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
 Omnes Startup accelerator & VC, Financial Services | Omnes Startup accelerator & VC, Financial Services | Other 17 Jan 2025 | | |
 Alexion Pharmaceuticals, Inc. Pharmaceutical, Biotechnology, Biotechnology Research | Alexion Pharmaceuticals, Inc. Pharmaceutical, Biotechnology, Biotechnology Research | Other 21 Jul 2024 | | |
 Pouss@LYS Financial Services | Pouss@LYS Financial Services | Other 7 Dec 2024 | | |
 AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | Other 21 Jul 2024 | | |
 Eurazeo Finance, Financial Services | Eurazeo Finance, Financial Services | Other 21 Feb 2024 | | |
 Auvergne-Rhone-Alpes Entreprises - Isère National and local authorities, Business Consulting and Services | Auvergne-Rhone-Alpes Entreprises - Isère National and local authorities, Business Consulting and Services | Other 31 Aug 2023 | | |
 La French Tech Media, Government Administration | La French Tech Media, Government Administration | Other 20 Aug 2024 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 13 Feb 2023 | | |
 Sofinnova Partners Financial Services | Sofinnova Partners Financial Services | Other 9 Sep 2024 | | |
 La French Tech Saint-Etienne Lyon French Tech, IT Services and IT Consulting | La French Tech Saint-Etienne Lyon French Tech, IT Services and IT Consulting | Other 13 Jun 2024 | | |